Ion channel regulators for the treatment of cystic fibrosis

Therapy

Volumn 8, Issue 6, 2011, Pages 661-670

  De Boeck, Christiane ^a   Cuppens, Harry ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Ataluren; CFTR; CFTR correctors; CFTR potentiatiors; Cystic fibrosis; Denufosol; ENaC; ENaC inhibitors; Ion channel regulators

Indexed keywords

ATALUREN; CHAPERONE; CHLORIDE CHANNEL; DENUFOSOL; EPITHELIAL SODIUM CHANNEL; IVACAFTOR; LANCOVUTIDE; LUBIPROSTONE; MIGLUSTAT; MUCOLYTIC AGENT; NEW DRUG; PLACEBO; SILDENAFIL; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VX 661; VX 809;

BREATHING EXERCISE; CLINICAL FEATURE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DIET THERAPY; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; GENE FUNCTION; GENE REPRESSION; HUMAN; NONHUMAN; NONSENSE MUTATION; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; REGULATOR GENE; REVIEW; SWEAT TEST;

EID: 81255154216     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.84     Document Type: Review

References (68)

1. Proesmans M, Vermeulen F, de Boeck K. What's new in cystic fibrosis?. From treating symptoms to correction of the basic defect. Eur. J. Pediatr. 167(8), 839-849 (2008).
2. Buzzetti R, Salvatore D, Baldo E et al. An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. J. Cyst. Fibros. 8(4), 229-237 (2009).
3. Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum. Mutat. 19(6), 575-606 (2002). (Pubitemid 34556480)
4. Munck A, Dhondt JL, Sahler C, Roussey M. Implementation of the French nationwide cystic fibrosis newborn screening program. J. Pediatr. 153(2), 228e1-233e1 (2008).
5. De Boeck K, Wilschanski M, Castellani C et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61(7), 627-635 (2006). (Pubitemid 44035145)
6. Borowitz D, Robinson KA, Rosenfeld M et al. Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis. J. Pediatr. 155(Suppl. 6), S73-S93 (2009).
7. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 62(4), 360-367 (2007). (Pubitemid 46580580)
8. Goubau C, Wilschanski M, Skalicka V et al. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax 64(8), 683-691 (2009).
9. Kerem BS, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245, 1073-1080 (1989). (Pubitemid 19231815)
10. Bombieri C, Claustres M, De Boeck K et al. Recommendations for the classification of diseases as CFTR-related disorders. J. Cyst. Fibros. 10(Suppl. 2), S86-S102 (2011).
11. Collaco JM, Blackman SM, McGready J, Naughton KM, Cutting GR. Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J. Pediatr. 157(5), 802-807 e1-e3 (2010).
12. Collaco JM, Vanscoy L, Bremer L et al. Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA 299(4), 417-424 (2008). (Pubitemid 351185950)
13. Riordan JR, Rommens JM, Kerem BS et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073 (1989). (Pubitemid 19231814)
14. Mall M, Bleich M, Greger R, Schreiber R, Kunzelmann K. The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J. Clin. Invest. 102(1), 15-21 (1998). (Pubitemid 28323825)
15. De Boeck K, Derichs N, Fajac I et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J. Cyst. Fibros. 10(Suppl. 2), S53-S66 (2011).
16. Chen JH, Stoltz DA, Karp PH et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 143(6), 911-923 (2010).
17. Moskwa P, Lorentzen D, Excoffon KJ et al. A novel host defense system of airways is defective in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175(2), 174-183 (2007). n An inactive oxidative antimicrobial system is described as an important cellular and molecular basis for defective cystic fibrosis (CF) airway immunity. (Pubitemid 46115089)
18. Jacquot J, Tabary O, Le Rouzic P, Clement A. Airway epithelial cell inflammatory signalling in cystic fibrosis. Int. J. Biochem. Cell Biol. 40(9), 1703-1715 (2008).
19. Hwang TC, Sheppard DN. Gating of the CFTR Cl-channel by ATP-driven nucleotide-binding domain dimerisation. J. Physiol. 587(Pt 10), 2151-2161 (2009).
20. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73, 1251-1254 (1993). (Pubitemid 23201140)
21. Kerem E, Hirawat S, Armoni S et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective Phase II trial. Lancet 372(9640), 719-727 (2008).
22. Kerem B, Rommens JM, Buchanan JA et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245(4922), 1073-1080 (1989). (Pubitemid 19231815)
23. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 361(9370), 1671-1676 (2003). (Pubitemid 36577438)
24. Thauvin-Robinet C, Munck A, Huet F et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J. Med. Genet. 46(11), 752-758 (2009).
25. Belcher CN, Vij N. Protein processing and inflammatory signaling in cystic fibrosis: challenges and therapeutic strategies. Curr. Mol. Med. 10(1), 82-94 (2010).
26. Thomas PJ, Pedersen PL. Effects of the d F508 mutation on the structure, function, and folding of the first nucleotide-binding domain of CFTR. J. Bioenerg. Biomembr. 25(1), 11-19 (1993). (Pubitemid 23036406)
27. Kalid O, Mense M, Fischman S et al. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J. Comput. Aided Mol. Des. 24(12), 971-991 (2010).
28. Wang Y, Loo TW, Bartlett MC, Clarke DM. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol. Pharmacol. 71(3), 751-758 (2007). (Pubitemid 46294086)
29. Hutt DM, Herman D, Rodrigues AP et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat. Chem. Biol. 6(1), 25-33 (2010).
30. Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol. Sci. 28(7), 334-341 (2007). nn Comprehensive information on cystic fibrosis transmembrane conductance regulator correctors and potentiators. (Pubitemid 47016687)
31. Van Goor F, Hadida S, Grootenhuis PDJ et al. Rescue of the protein folding defect in cystic fibrosis in vitro by the investigational small molecule, VX-809. J. Cys. Fibros. 9(Suppl. 1), S14-S14 (2010).
32. Clancy JP, Spencer-Green G. Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. J. Cys. Fibros. 9(Suppl. 1), S20-S20 (2010).
33. Benito JM, Garcia Fernandez JM, Ortiz Mellet C. Pharmacological chaperone therapy for Gaucher disease: a patent review. Expert Opin. Ther. Pat. 21(6), 885-903 (2011).
34. Noel S, Wilke M, Bot AG, De Jonge HR, Becq F. Parallel improvement of sodium and chloride transport defects by miglustat (N-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J. Pharmacol. Exp. Ther. 325(3), 1016-1023 (2008). (Pubitemid 351724326)
35. Van Goor F, Yu H, Burton B et al. Investigational compound VX-770 potentiated multiple CFTR channel gating mutants in vitro. J. Cys. Fibros. 10(Suppl. 1), S16-S16 (2011).
36. Accurso FJ, Rowe SM, Clancy JP et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363(21), 1991-2003 (2010).
37. Lubamba B, Lebacq J, Reychler G et al. Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. Eur. Respir. J. 37(1), 72-78 (2011).
38. Mall M, Kunzelmann K. Correction of the CF defect by curcumin: hypes and disappointments. BioEssays 27(1), 9-13 (2005). (Pubitemid 40128617)
39. Singh OV, Pollard HB, Zeitlin PL. Chemical rescue of d F508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells. Mol. Cell Proteomics 7(6), 1099-1110 (2008). (Pubitemid 351943957)
40. Yu YC, Miki H, Nakamura Y et al. Curcumin and genistein additively potentiate G551D-CFTR. J. Cyst. Fibros. 10(4), 243-252 (2011).
41. Fischer H, Schwarzer C, Illek B. Vitamin C controls the cystic fibrosis transmembrane conductance regulator chloride channel. Proc. Natl Acad. Sci. USA 101(10), 3691-3696 (2004). (Pubitemid 38338256)
42. Sermet-Gaudelus I, Boeck KD, Casimir GJ et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med. 182(10), 1262-1272 (2010).
43. Wilschanski M, Miller LL, Shoseyov D et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur. Respir. J. 38(1), 59-69 (2011).
44. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N. Engl.J. Med. 325(8), 533-538 (1991).
45. Accurso FJ, Moss RB, Wilmott RW et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am. J. Respir. Crit. Care Med. 183(5), 627-634 (2011).
46. Oliynyk I, Varelogianni G, Roomans GM, Johannesson M. Effect of duramycin on chloride transport and intracellular calcium concentration in cystic fibrosis and non-cystic fibrosis epithelia. APMIS 118(12), 982-990 (2010).
47. Yang YD, Cho H, Koo JY et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455(7217), 1210-1215 (2008).
48. Rock JR, O'Neal WK, Gabriel SE et al. Transmembrane protein 16A (TMEM16A) is a Ca2+ regulated Cl-secretory channel in mouse airways. J. Biol. Chem. 284(22), 14875-14880 (2009).
49. Anderson MP, Sheppard DN, Berger HA, Welsh MJ. Chloride channels in the apical membrane of normal and cystic fibrosis airway and intestinal epithelia. Am. J. Physiol. 263(Pt 1), L1-L14 (1992).
50. Lacy BE, Campbell Levy L. Lubiprostone: a chloride channel activator. J. Clin. Gastroenterol. 41(4), 345-351 (2007). (Pubitemid 46573059)
51. Schwiebert EM, Cid-Soto LP, Stafford D et al. Analysis of ClC-2 channels as an alternative pathway for chloride conduction in cystic fibrosis airway cells. Proc. Natl Acad. Sci. USA 95(7), 3879-3884 (1998). (Pubitemid 28173222)
52. MacDonald KD, McKenzie KR, Henderson MJ, Hawkins CE, Vij N, Zeitlin PL. Lubiprostone activates non-CFTRdependent respiratory epithelial chloride secretion in cystic fibrosis mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 295(5), L933-L940 (2008).
53. Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J. Aerosol Med. Pulm. Drug Deliv. 21(1), 13-24 (2008).
54. Kerem E, Bistritzer T, Hanukoglu A et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N. Engl. J. Med. 341(3), 156-162 (1999). (Pubitemid 29325743)
55. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 10(5), 487-493 (2004). (Pubitemid 38667907)
56. Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N. Engl. J. Med. 347(6), 401-407 (2002). (Pubitemid 34851832)
57. Azad AK, Rauh R, Vermeulen F et al. Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease. Hum. Mutat. 30(7), 1093-1103 (2009).
58. Pons G, Marchand MC, d'Athis P et al. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The amiloride-AFLM collaborative study group. Pediatr. Pulmonol. 30(1), 25-31 (2000). (Pubitemid 30413945)
59. Hirsh AJ, Zhang J, Zamurs A et al. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-Ń-4-[4-(2,3-dihydroxypropoxy) phenyl] butyl-guanidine methanesulfonate (552-502), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J. Pharmacol. Exp. Ther. 325(1), 77-88 (2008). (Pubitemid 351439164)
60. Sobczak K, Bangel-Ruland N, Semmler J, Lindemann H, Heermann R, Weber WM. Antisense oligonucleotides for therapy of cystic fibrosis. Inhibition of sodium absorption mediated by ENaC in nasal epithelial cells. HNO 57(11), 1106-1112 (2009).
61. Okiyoneda T, Barriere H, Bagdany M et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329(5993), 805-810 (2010).
62. Belcher CN, Vij N. Protein processing and inflammatory signaling in cystic fibrosis: challenges and therapeutic strategies. Curr. Mol. Med. 10(1), 82-94 (2011).
63. Phuan PW, Yang B, Knapp JM et al. Cyanoquinolines with independent corrector and potentiator activities restore dphe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. Mol. Pharmacol. 80(4), 683-693 (2011).
64. Konstan MW, Wagener JS, Yegin A, Millar SJ, Pasta DJ, VanDevanter DR. Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint. J. Cyst. Fibros. 9(5), 332-338 (2010).
65. Zhou Z, Treis D, Schubert SC et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in b-ENaC-overexpressing mice. Am. J. Respir. Crit. Care Med. 178(12), 1245-1256 (2008).
66. Elborn S. Oral communication ECFS conference June 2011, Late brake science. (2011).
67. Fischer D, Tessari M, Roseboom M et al. Identification and validation of novel drug targets to treat cystic fibrosis. Pediatr. Pulmonol. 43(S31), 213 (2008).
68. Carlile GW, Robert R, Zhang D et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem. 8(9), 1012-1020 (2007). (Pubitemid 47189285)